Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Kelly, W. K.; Danila, D. C.; Edenfield, W. J.; Aggarwal, R. R.; Petrylak, D. P.; Sartor, A. O.; Sumey, C. J.; Dorff, T. B.; Yu, E. Y.; Adra, N.; Waterhouse, D. M.; Armstrong, A. J.; Horvath, L.; Pook, D. W.; Appleman, L. J.; Lau, A.; Salvati, M.; Kouros-Mehr, H. |
| Abstract Title: | Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309163 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS5589 |
| Notes: | Meeting Abstract: TPS5589 -- Source: Wos |
